Application value of five lymph node staging methods in predicting prognosis of perihilar cholangiocarcinoma
严笑鹏,伏旭,陈潇远,杨翼飞,蔡正华,凡银银,仇毓东,毛谅,周铁,张静
DOI: https://doi.org/10.3760/cma.j.cn115610-20201208-00767
2021-01-01
Abstract:Objective:To investigate the application value of 5 different lymph node staging methods in predicting prognosis of perihilar cholangiocarcinoma(PHCC), including the pN stage of American Joint Committee on Cancer (AJCC) 8th edition TNM staging system, the number of positive lymph nodes(pLN), the number of negative lymph nodes(pLN), lymph node ratio(LNR), and log odds of metastatic lymph nodes(LODDS).Methods:The retrospective cohort study was conducted. The clinicopathological data of 669 PHCC patients from 2004 to 2015 in the Surveillance, Epidemiology, and End Results (SEER) database of America were collected. There were 406 males and 263 females, aged (66±11) years, with a range from 29 to 92 years. Observation indicators: (1) prognostic factor analysis of PHCC patients; (2) follow-up and survival of PHCC patients; (3) comparison of prognosis between patients in N1 stage and patients in N2 stage grouped by 5 different lymph node staging methods; (4) accuracy of 5 different lymph node staging methods in predicting prognosis of PHCC patients. Measurement data with normal distribution were represented as Mean±SD, and measurement data with skewed distribution were represented as M (range). Count data were described as absolute numbers and percentages. The Kaplan-Meier method was used to calculate survival rates and draw survival curves. The Log-rank test was used for univariate survival analysis. Multivariate survival analysis was performed using the COX proportional hazard model. X-tile 3.6.1 software was used to determine the optimal cut-off values of pLN, nLN, LNR and LODDS, and they were converted to categorical variables. Patients with regional lymph node metastasis were divided into patients in N1 stage and N2 stage based on pN stage of the AJCC 8th edition TNM staging system and optimal cut-off values of pLN, nLN, LNR and LODDS in X-tile software. Akaike information criterion (AIC), Harrell's Consistency Index (C-index) and 1-, 3-, 5-year area under receiver operating curve (AUROC) were calculated to compare prognostic performance of different staging methods. Results:(1) Prognostic factor analysis of PHCC patients: results of univariate analysis showed that tumor differentiation degree, tumor length, pT stage, regional lymph node metastasis were related factors for prognosis of PHCC patients ( χ2=17.893, 10.196, 25.177, 76.707, P<0.05). Results of multivariate analysis showed that poorly differentiated or undifferentiated tumor, pT3-pT4 stage, regional lymph node metastasis were independent risk factors for prognosis of patients ( hazard ratio=1.384, 1.262, 2.067, 95% confidence interval as 1.145-1.673, 1.032-1.543, 1.698-2.515, P<0.05). (2) Follow-up and survival of PHCC patients: all the 669 patients received the follow-up. In the cohort, the cancer-specific survival time was 1-167 months, with a median survival time of 26 months, and the 1-, 3-, 5-year cancer-specific survival rates were 76.5%, 40.7%, 32.1%, respectively. For 359 of the 669 patients without regional lymph node metastasis, the cancer-specific survival time was 1-167 months, with a median survival time of 45 months, and the 1-, 3-, 5-year cancer-specific survival rates were 84.2%, 54.1%, 45.0%, respectively. For 310 of the 669 patients with regional lymph node metastasis, the cancer-specific survival time was 1-160 months, with a median survival time of 17 months, and the 1-, 3-, 5-year cancer-specific survival rates were 67.3%, 25.0%, 16.7%, respectively. There was a significant difference in the cancer-specific survival rate between the two groups ( χ2=76.707, P<0.05). (3) Comparison of prognosis between patients in N1 stage and patients in N2 stage grouped by 5 different lymph node staging methods: of the 310 patients with regional lymph node metastasis, according to the pN stage of AJCC 8th edition TNM staging system, 228 patients in N1 stage (1≤pLN≤3) had 1-, 3-, 5-year cancer-specific survival rates of 69.0%, 26.6%,18.1%, 82 patients in N2 stage (pLN≥4) had 1-, 3-, 5-year cancer-specific survival rates of 62.3%,20.1%, 12.3%, respectively, showing no significant difference between the two groups ( χ2=2.294, P>0.05). According to the pLN, 251 patients in N1 stage (1≤pLN≤4) had 1-, 3-, 5-year cancer-specific survival rates of 69.1%, 27.1%, 19.3%, 59 patients in N2 stage (pLN≥5) had 1-, 3-, 5-year cancer-specific survival rates of 59.2%,15.2%,3.8%, respectively, showing a significant difference between the two groups ( χ2=7.213, P<0.05). According to the nLN, 70 patients in N1 stage (nLN≥16) had 1-, 3-, 5-year cancer-specific survival rates of 73.9%, 31.9%, 22.2%, 240 patients in N2 stage (nLN≤15) had 1-, 3-, 5-year cancer-specific survival rates of 65.3%,22.9%,15.0%, respectively, showing a significant difference between the two groups ( χ2=4.805, P<0.05). According to the LNR, 184 patients in N1 stage (LNR≤0.32) had 1-, 3-, 5-year cancer-specific survival rates of 74.2%, 29.7%,19.9%, 126 patients in N2 stage (LNR>0.32) had 1-, 3-, 5-year cancer-specific survival rates of 56.9%,18.0%,11.9%, respectively, showing a significant difference between the two groups ( χ2=9.273, P<0.05). According to the LODDS, 185 patients in N1 stage (LODDS≤-0.65) had 1-, 3-, 5-year cancer-specific survival rates of 74.3%, 29.5%, 18.4%, 125 patients in N2 stage (LODDS>-0.65) had 1-, 3-, 5-year cancer-specific survival rates of 56.6%, 19.8%,12.1%, respectively, showing a significant difference between the two groups ( χ2=9.584, P<0.05). (4) Accuracy of 5 different lymph node staging methods in predicting prognosis of PHCC patients: the AUROC for 1-year cancer-specific survival rates were 0.530, 0.534, 0.534, 0.594,0.597 based on the AJCC 8th edition pN stage, pLN, nLN, LNR, LODDS, the AUROC for 3-year cancer-specific survival rates were 0.534, 0.549, 0.542, 0.571,0.575, and the AUROC for 5-year cancer-specific survival rates were 0.531, 0.568, 0.553, 0.566, 0.570, respectively. The AIC values were 2 472.768, 2 468.430, 2 469.987, 2 466.035, 2 465.737, and the C-index were 0.529, 0.531, 0.535, 0.563, 0.564, respectievly. LODDS had the maximum AUROC for 1-, 3-, 5-year cancer-specific survival rates and C-index score but the minimum AIC value, showing the highest accuracy in predicting prognosis of PHCC patients. Conclusion:Poorly differentiated or undifferen-tiated tumor, pT3-pT4 stage, regional lymph node metastasis are independent risk factors for prognosis of patients. LODDS has the maximum AUROC for cancer-specific survival rates in PHCC patients and C-index score but the minimum AIC value.